Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab) in seven European countries. Breast cancer blockbuster Herceptin earned $2.26 billion in ...
Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback